Journal
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
Volume 11, Issue 6, Pages 645-653Publisher
HARBORSIDE PRESS
DOI: 10.6004/jnccn.2013.0084
Keywords
-
Categories
Funding
- Exelixis Inc.
- Abraxis Oncology
- Boehringer Ingelheim GmbH
- Celgene Corporation
- Genentech, Inc.
- GlaxoSmithKline
- Pfizer Inc
- Pharmacyclics
- Eli Lilly and Company
- Eisai, Inc.
- Millennium
- Takeda Oncology Company
- Teva Pharmaceuticals
- Bayer HealthCare Pharmaceuticals Inc.
- Endo Pharmaceuticals and HealthTronics
- Genentech
- ARIAD Pharmaceuticals, Inc.
Ask authors/readers for more resources
These NCCN Guidelines Insights focus on the diagnostic evaluation of suspected lung cancer. This topic was the subject of a major update in the 2013 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer. The NCCN Guidelines Insights focus on the major updates in the NCCN Guidelines and discuss the new updates in greater detail.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
